BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36306447)

  • 1.
    Rani S; Sahoo RK; Kumar V; Chaurasiya A; Kulkarni O; Mahale A; Katke S; Kuche K; Yadav V; Jain S; Nakhate KT; Ajazuddin ; Gupta U
    Mol Pharm; 2023 Jan; 20(1):524-544. PubMed ID: 36306447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
    Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
    Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biotinylated HPMA centered polymeric nanoparticles for Bortezomib delivery.
    Rani S; Sahoo RK; Nakhate KT; Ajazuddin ; Gupta U
    Int J Pharm; 2020 Apr; 579():119173. PubMed ID: 32097684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sialic Acid Engineered Prodrug Nanoparticles for Codelivery of Bortezomib and Selenium in Tumor Bearing Mice.
    Rani S; Sahoo RK; Mahale A; Panchal K; Chaurasiya A; Kulkarni O; Kuche K; Jain S; Nakhate KT; Ajazuddin ; Gupta U
    Bioconjug Chem; 2023 Sep; 34(9):1528-1552. PubMed ID: 37603704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycine-Poly-L-Lactic Acid Copolymeric Nanoparticles for the Efficient Delivery of Bortezomib.
    Rajoria S; Rani S; Chaudhari D; Jain S; Gupta U
    Pharm Res; 2019 Sep; 36(11):160. PubMed ID: 31520196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
    Yin YP; Shi WH; Deng K; Liu XL; Li H; Lv XT; Lui VWY; Ding C; Hong B; Lin WC
    Acta Pharmacol Sin; 2021 Aug; 42(8):1298-1310. PubMed ID: 33139838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual pH-Responsive Shell-Cleavable Polycarbonate Micellar Nanoparticles for in Vivo Anticancer Drug Delivery.
    Liu S; Ono RJ; Yang C; Gao S; Ming Tan JY; Hedrick JL; Yang YY
    ACS Appl Mater Interfaces; 2018 Jun; 10(23):19355-19364. PubMed ID: 29757607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer.
    Xiao K; Li YP; Wang C; Ahmad S; Vu M; Kuma K; Cheng YQ; Lam KS
    Biomaterials; 2015 Oct; 67():183-93. PubMed ID: 26218744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catechol polymers for pH-responsive, targeted drug delivery to cancer cells.
    Su J; Chen F; Cryns VL; Messersmith PB
    J Am Chem Soc; 2011 Aug; 133(31):11850-3. PubMed ID: 21751810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multifunctional Telodendrimer Nanocarriers Restore Synergy of Bortezomib and Doxorubicin in Ovarian Cancer Treatment.
    Wang L; Shi C; Wright FA; Guo D; Wang X; Wang D; Wojcikiewicz RJH; Luo J
    Cancer Res; 2017 Jun; 77(12):3293-3305. PubMed ID: 28396359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The γ-secretase inhibitor GSI-I interacts synergistically with the proteasome inhibitor bortezomib to induce ALK+ anaplastic large cell lymphoma cell apoptosis.
    Dang Q; Chen L; Xu M; You X; Zhou H; Zhang Y; Shi W
    Cell Signal; 2019 Jul; 59():76-84. PubMed ID: 30878517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
    Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
    Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of pH-Active Catechol-Bearing Polymeric Nanogels with Glutathione-Responsive Dissociation to Codeliver Bortezomib and Doxorubicin for the Synergistic Therapy of Cancer.
    Qiu Y; Bai J; Feng Y; Shi X; Zhao X
    ACS Appl Mater Interfaces; 2021 Aug; 13(31):36926-36937. PubMed ID: 34319074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib-loaded mixed micelles realize a "three-in-one" effect for enhanced breast cancer treatment.
    Liu J; Xu X; Li Y; Xu J; Zhao R; Liu S; Wu J; Zhang L; Zhang B
    Biomater Sci; 2023 Jul; 11(14):4890-4906. PubMed ID: 37306225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations.
    Liu J; Zhao R; Jiang X; Li Z; Zhang B
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEGylated Dendrimer Mediated Delivery of Bortezomib: Drug Conjugation versus Encapsulation.
    Sahoo RK; Gothwal A; Rani S; Nakhate KT; Ajazuddin ; Gupta U
    Int J Pharm; 2020 Jun; 584():119389. PubMed ID: 32380027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to bortezomib in breast cancer cells that downregulate Bim through FOXA1 O-GlcNAcylation.
    Liu Y; Wang X; Zhu T; Zhang N; Wang L; Huang T; Cao Y; Li W; Zhang J
    J Cell Physiol; 2019 Aug; 234(10):17527-17537. PubMed ID: 30793308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib-catechol conjugated prodrug micelles: combining bone targeting and aryl boronate-based pH-responsive drug release for cancer bone-metastasis therapy.
    Zhu J; Huo Q; Xu M; Yang F; Li Y; Shi H; Niu Y; Liu Y
    Nanoscale; 2018 Oct; 10(38):18387-18397. PubMed ID: 30256367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
    Kim A; Seong KM; Kang HJ; Park S; Lee SS
    Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
    Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
    Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.